Novasite Pharmaceuticals aims to enhance small molecule drug discovery and optimization using AME's proprietary directed evolution technology. Novasite's proprietary Expanded Target Drug Discoveryª technology is being developed to screen at high throughput large chemical libraries against thousands of variants of the target's binding site. The expanded recognition properties of the variant target library enable the identification of novel and high potency leads. Bioinformatic analysis of the large amount of data regarding specific ligand-receptor interactions obtained serves to guide the lead optimization process.